Cardiol Therapeutics Inc. Class A · TSX:CRDL
Cardiol Therapeutics Inc. Class A — Investor Presentation (January 2022)
31 slides from Cardiol Therapeutics Inc. Class A's investor presentation, January 2022
Slide 1: Cardiol Therapeutics Corporate Presentation January 2022
NASDAQ: CRDL | TSX: CRDL Clinical-stage Life Sciences Company Focused on the Research and Clinical Development of Anti-inflammatory Therapies for the Treatment of Cardiovascular Disease JANUARY 2022 Copyright © 2022 Cardiol Therapeutics Inc.
Slide 2: Disclaimer
Disclaimer In this presentation, all amounts are in Canadian dollars, unless otherwise indicated. Any graphs, tables or other information in this presentation demonstrating the historical performance of Cardiol Therapeutics Inc. (“Cardiol”) or any other entity contained in this presentation are inte
Slide 3: Cardiol Therapeutics Today
Cardiol Therapeutics Today SCIENTIFIC CLINICAL INTELLECTUAL LEADERSHIP PIPELINE RATIONAL PROGRAMS PROPERTY Experienced leadership Compelling evidence INDs cleared for Research focused on Comprehensive with extensive expertise supporting Phase II and Phase II/III the development of intellectual prope
Slide 4: Evidence Supporting Cannabidiol Use For Inflammatory Heart Disease
2 - Cardiol Therapeutics Inc. Evidence Supporting Cannabidiol Use For Inflammatory Heart Disease • Attenuates cardiac dysfunction and reduces inflammation in a model of diabetic cardiomyopathy. • Significantly decreases cardiac fibrosis (scarring of the heart muscle) in a non-ischemic model of heart
Slide 5: Oral Cannabidiol Formulation
2 - Cardiol Therapeutics Inc. • High-concentration oral cannabidiol formulation for acute inflammatory heart disease. Oral Cannabidiol Formulation* • In Phase II/III clinical development as a cardiorespiratory protective drug for patients with acute inflammatory heart disease. • Manufactured under c
Slide 6: CardiolRx – Clinical Development Programs
CardiolRx™ – Clinical Development Programs INDICATION Pre-clinical Phase I Phase II Phase III HIGH-RISK PATIENTS WITH CARDIOVASCULAR DISEASE, HOSPITALIZED WITH COVID-19 ORAL FORMULATION ACUTE MYOCARDITIS DIASTOLIC SUBCUTANEOUS HEART FAILURE FORMULATION NASDAQ: CRDL | TSX: CRDL CardiolRx.com | 6
Slide 7: How Cannabidiol Protects the Heart in Models of Cardiovascular Disease
How Cannabidiol Protects the Heart in Models of Cardiovascular Disease Evidence Supporting Therapeutic Potential in Acute and Chronic Inflammatory Heart Disease • Reduces inflammation and improves endothelial dysfunction • Reduces cardiac inflammatory cytokine levels in a model of myocarditis (infla
Slide 8: Steering Committee for Clinical Development Programs
Steering Committee for Clinical Development Programs Dennis M. McNamara, MD Leslie T. Cooper, Jr., MD Barry Trachtenberg, MD Chair Co-Chair Cardiologist specializing in heart Professor of Medicine at the General cardiologist and the failure and cardiac transplantation. University of Pittsburgh. He i
Slide 9: LANCER Trial
LANCER Trial Phase II/III Trial designed to investigate the cardiorespiratory protective properties of CardiolRx™ in patients hospitalized with COVID-19 who have a prior history of, or risk factors for, cardiovascular disease N ASDAQ TSX:CRDL : C R D L | FSE:CT9 OTCQX:CRTPF TSX: CRDL CardiolRx.com |
Slide 10: COVID-19 Patients with CVD Complications Have Lower Survival Rates
COVID-19 Patients with CVD Complications Have Lower Survival Rates Journal of the American Medical Association Mortality During Hospitalization Between Patients With vs. Without Cardiac Injury Time from symptom onset 100 - • COVID-19 patients with cardiac injury had WITHOUT CARDIAC INJURY a higher m
Slide 11: CardiolRx – Phase II/III Clinical Development Program
CardiolRx™ – Phase II/III Clinical Development Program IND application cleared by FDA Multi-national, double-blind, placebo-controlled trial to investigate the cardiorespiratory protective properties of CardiolRx™ in patients hospitalized with COVID-19 who have a prior history of, or risk factors fo
Slide 12: Phase II/III LANCER Study Design
Phase II/III LANCER Study Design Hospitalized COVID-19 Patients with Cardiovascular Disease or Risk Factors Tested positive within 7 days and randomization within 48 hours of admission RANDOMIZED 1:1 DOUBLE BLIND PLACEBO 2.5 mg/kg to 7.5 mg/kg b.i.d Primary endpoint after 28 days treatment: Death, I
Slide 13: Acute Myocarditis
Acute Myocarditis Orphan Drug Indication* Investigational New Drug (IND) application cleared for Phase II clinical trial of CardiolRx™ for treatment in acute myocarditis *The Company has not yet received Orphan Drug Designation from the FDA. NASDAQ: CRDL | TSX: CRDL CardiolRx.com | 13
Slide 14: CardiolRx – Acute Myocarditis
2 - Cardiol Therapeutics Inc. CardiolRx™ – Acute Myocarditis • Inflammatory condition of the heart most often resulting from viral infection. MYOCARDITIS • A major cause of sudden death in children and young adults. • Can progress to dilated cardiomyopathy and heart failure. Inflammation of Heart Mu
Slide 15: Acute Myocarditis – Potential for Orphan Drug Designation
2 - Cardiol Therapeutics Inc. Acute Myocarditis – Potential for Orphan Drug Designation Acute Myocarditis U.S. Patient Estimate (Prevalence) 73,000 Orphan Drugs in the United States • Fewer than 200,000 cases required to qualify as Orphan Drug. • Potential for Fast Track regulatory development and a
Slide 16: Cannabidiol Attenuates Myocarditis-induced Fibrosis
Cannabidiol Attenuates Myocarditis-induced Fibrosis Effect of Cannabidiol on Heart Fibrosis Experimental Model of Autoimmune Myocarditis (EAM) Sections of Heart Tissue - Fibrosis HEALTHY TISSUE MYOCARDITIS MYOCARDITIS + CBD Representative images of Sirius red-stained LV myocardium sections. Magnific
Slide 17: CardiolRx – Acute Myocarditis Clinical Development Program
2 - Cardiol Therapeutics Inc. CardiolRx™ – Acute Myocarditis Clinical Development Program IND application cleared by FDA for global Phase II trial Multi-center, double-blind, randomized, placebo-controlled trial designed to study the safety and tolerability of CardiolRx™, as well as its impact on my
Slide 18: Acute Myocarditis Study Design
2 - Cardiol Therapeutics Inc. Acute Myocarditis Study Design Clinical diagnosis of acute myocarditis within the previous 90 days Confirmed by: Cardiac Magnetic Resonance (CMR) OR Endomyocardial biopsy RANDOMIZED 1:1 DOUBLE BLIND PLACEBO 2.5 mg/kg to 10 mg/kg b.i.d Primary Endpoint: Improvement in CM
Slide 19: Heart Failure
Heart Failure Developing a Proprietary Subcutaneous Cannabidiol Formulation of CardiolRx™ for Chronic Heart Failure NASDAQ: CRDL | TSX: CRDL CardiolRx.com | 19
Slide 20: Heart Failure – A Leading Cause of Death and Disability
2 - Cardiol Therapeutics Inc. Heart Failure – A Leading Cause of Death and Disability Developing a Proprietary Subcutaneous Cannabidiol Formulation to Target Inflammation in the Heart • Over 6 million adults in Canada and the U.S. suffer from heart failure(1). • About half of all heart failure patie
Slide 21: The Issue: Overview of Diastolic Heart Failure
2 - Cardiol Therapeutics Inc. The Issue: Overview of Diastolic Heart Failure Occurs when the heart fails to relax normally and fill with blood which is required to oxygenate tissues of the body HEALTHY HEART DIASTOLIC HEART FAILURE Left atrium Right atrium Thickened Left ventricular Right ventricle
Slide 22: International Research Collaborations
International Research Collaborations Developing Subcutaneous Cannabidiol Formulation for Heart Failure • TecSalud del Tecnológico de Monterrey and DeBakey Heart & Vascular Center. • Research producing scientific and pre-clinical data to support clinical development. • Cardioprotection demonstrated
Slide 23: Subcutaneous Cannabidiol Formulation
2 - Cardiol Therapeutics Inc. • Subcutaneous formulation to achieve higher bioavailability than an oral formulation. Subcutaneous Cannabidiol Formulation • Anti-fibrotic activity of cannabidiol to prevent progressive fibrosis (scarring) in the heart muscle. • Anti-inflammatory activity of cannabidio
Slide 24: Cardioprotective Properties of Subcutaneous Cannabidiol Formulation (BNP)
Cardioprotective Properties of Subcutaneous Cannabidiol Formulation Demonstrated in a Non-ischemic Model of Heart Failure Measurements of BNP mRNA expression in heart tissue 5- Groups treated with Cannabidiol *** BNP mRNA BNP/GAPDH at 1 or 10 mg/kg show attenuated 4- (fold change) BNP increase seen
Slide 25: Cardioprotective Properties of Subcutaneous Cannabidiol Formulation (Fibrosis)
Cardioprotective Properties of Subcutaneous Cannabidiol Formulation Demonstrated in a Non-ischemic Model of Heart Failure Cardiol’s research shows cannabidiol reduces the development of angiotensin-induced fibrosis: histopathologic analysis of heart tissue Heart Sections Stained with Masson’s Tricho
Slide 26: Milestones
Milestones 2021 Milestones Upcoming Milestones ü Reported results from a Phase I single and 1. Complete patient enrollment and report top multiple ascending dose clinical trial of line results in the Phase II/III international CardiolRx™. LANCER trial examining the cardioprotective ü Initiated enrol
Slide 27: Experienced Management Team
Experienced Management Team David Elsley, MBA Andrew Hamer, MB, ChB President and Chief Executive Officer Chief Medical Officer Founder and former President and CEO Thirty years of global life sciences industry, of Vasogen Inc. More than 30 years’ medical affairs, and cardiology practice experience.
Slide 28: Strong Board of Directors
Strong Board of Directors Guillermo Torre-Amione, MD, PhD David Elsley, MBA Chairman President and Chief Executive Officer Professor of Cardiology at the Methodist Hospital Founder and former President and CEO of Research Institute, Professor of Medicine at the Weill Vasogen Inc. More than 30 years’
Slide 29: Capital Structure
Capital Structure NASDAQ: CRDL | TSX: CRDL Common Shares Outstanding 61.0 M Fully Diluted Common Shares 79.5 M Insider and Employee Ownership 12% Pharmaceutical Partners & Research Collaborators 4% Cash and Cash Equivalents as of November 11, 2021(1) $85.7 M Current Debt $0.0 M (1) As of the date of
Slide 30: Cardiol Therapeutics Today
Cardiol Therapeutics Today SCIENTIFIC CLINICAL INTELLECTUAL LEADERSHIP PIPELINE RATIONAL PROGRAMS PROPERTY Experienced leadership Compelling evidence INDs cleared for Research focused on Comprehensive with extensive expertise supporting Phase II and Phase II/III the development of intellectual prope
Slide 31: Contact Information
NASDAQ: CRDL | TSX: CRDL Contact Information E: Investor.relations@cardiolrx.com T: +1 289.910.0850 W: CardiolRx.com Copyright © 2022 Cardiol Therapeutics Inc.
Cardiol Therapeutics — Investor Presentation (January 2022) on 6ix